Table 1.
Description of the population at the time of diagnosis of the primary tumour
| Demographic characteristics (n=48) | |
| Mean age at diagnosis—years±SD | 50.6±11.6 |
| Interval—years | (27–80) |
| Age ≤50 years old—n (%) | 25 (52.1) |
| Median survival since the onset of liver metastases—months (95% CI) | 25.5 (20.1 to 40.4) |
| Median survival since the appearance of liver contour abnormalities—months (95% CI) | 8.5 (6.7 to 10.8) |
| Alcohol abuse | |
| Yes—n (%) (95% CI for %)* | 2 (4.2) (1.2 to 14.0) |
| No—n (%) (95% CI for %) | 40 (83.3) (70.4 to 91.3) |
| N/A—n (%) (95% CI for %) | 6 (12.5) (5.9 to 24.7) |
| n (%) (95% CI for %) | Control—n (%) (95% CI for %)† | |
| Histological subtypes (n=44) | ||
| Ductal | 32 (72.7) (58.1 to 83.7) | 4149 (79.5) (78.4 to 80.6) |
| Lobular | 10 (22.7) (12.8 to 37.0) | 671 (12.9) (12.0 to 13.8) |
| Mixed | 1 (2.3) (0.4 to 11.8) | 215 (4.1) (3.6 to 4.7) |
| Others | 1 (2.3) (0.4 to 11.8) | 184 (3.5) (3.1 to 4.1) |
| P value: Fisher’ exact test | 0.27 | |
| Disease subtypes (n=34)‡ | ||
| Luminal | 30 (88.2) (73.4 to 95.3) | 3517 (69.6) (68.3 to 79.9) |
| Luminal A | 8 | – |
| Luminal B§ | 13 | – |
| Ki67 not available | 9 | – |
| HER2 positive | 3 (8.8) (3.0 to 23.0) | 803 (15.9) (14.9 to 16.9) |
| Triple negative | 1 (2.9) (0.5 to 14.9) | 737 (14.6) (13.7 to 15.6) |
| P value: X2 test | 0.052 | |
| Difference in disease subtypes in our population and the control | |
| Luminal difference | 18.6% (95% CI for the difference: 3.7% to 25.8%) |
| HER2 positive difference | 7.1% (95% CI for the difference: −12.9% to 7.1 %) |
| Triple negative difference | 11.7% (95% CI for the difference: −14.3% to 0.4%) |
*>20 g alcohol/day.
†Data of primary tumours diagnosed at the Jules Bordet Institute for all patients enrolled in the cancer registry between 2010 and 2017.
‡14 patients did not have labelling for HER2 protein.
§ Ki67 ≥20%.
n, number of patients in the category; NA, not applicable.